Barinthus Biotherapeutics

BRNS

時価総額 $3023万

Here is how Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) and Agilent Technologies (A) have performed compared to their sector so far this year.

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. (“Clywedog”) in an all-stock transaction.

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026 GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company's corporate developments.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate,.

GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company's corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SAN DIEGO , Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing.

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Barinthus Biotherapeutics plc (NASDAQ: BRNS ) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depository Share or ordinary share owned, and Clywedog shareholders will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned. Is it a fair deal?

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned, and Clywedog shareholder.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Barinthus Biotherapeutics plc (NASDAQ: BRNS) and Clywedog Therapeutics, Inc. is fair to Barinthus shareholders. Under the terms of the agreement, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned, and Clywedog shareholders will receive 4.358932 shares of common stock in the new combined.